Update March 12, 2020: H.R. 5534 passed unanimously in the House Energy and Commerce Health Subcommittee on March 11. Extended Medicare coverage of immunosuppressive drugs will help kidney recipients avoid situations where they struggle to pay for their needed medications and other necessities. READ MORE >>

The American Kidney Fund (AKF) submitted a comment letter to the Center for Medicare & Medicaid Services (CMS) regarding their proposed rule on the End-Stage Renal Disease (ESRD) Treatment Choices Model (ETC model). READ MORE >>

According to a new analysis from the U.S. Department of Health and Human Services (HHS), extending Medicare immunosuppressive drug coverage for kidney transplant recipients for more than three years post-transplant would result in Medicare savings of $73.4 million over 10 years. READ MORE >>

The Centers for Medicare and Medicaid Services (CMS) released a final rule that upholds the existing rules on the six protected classes of drugs in the Medicare Part D program. READ MORE >>

The American Kidney Fund (AKF) submitted a comment letter to the Centers for Medicare and Medicaid Services (CMS) that voiced our concern on proposed changes to the six protected classes of drugs in the Medicare program. READ MORE >>

In preparation for a new Congress and the start of the state legislative sessions, the American Kidney Fund did some ground work to educate elected officials on Medigap in December. READ MORE >>

On January 29, Alex Azar was sworn in as the new secretary for the U.S. Department of Health Human Services (HHS). READ MORE >>

Since 1972, most people with end-stage renal disease (ESRD) become eligible for Medicare, and most of them choose to enroll in the program as their primary health insurance coverage. READ MORE >>